-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Douglas K. Owens, MD

Articles by Douglas K. Owens, MD

Improving Patient-Centered Care in Diabetes With Comparative Effectiveness Research

ByDouglas K. Owens, MD,Wade Aubry, MD,Roy Beck, MD,Joshua Benner, MD,Jan E. Berger, PharmD,Michael E. Chernew, PhD,Felicia Forma, BSc,Dana P. Goldman, PhD,William H. Herman, MD,Rebecca Killion, MA,Darius Lakdawalla, PhD,Anne L Peters, MD

September 30th 2013

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes

ByMichael E. Chernew, PhD,Rick McKellar, BS,Wade Aubry, MD,Roy Beck, MD, PhD,Joshua Benner, PharmD, ScD,Jan E. Berger, MD, MJ,A. Mark Fendrick, MD,Felicia Forma, BSc,Dana Goldman, PhD,Anne Peters, MD,Rebecca Killion, MA,Darius Lakdawalla, PhD,Douglas K. Owens, MD,Joe Stahl, MA

July 2nd 2013

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes

ByMichael E. Chernew, PhD,Rick McKellar, BS,Wade Aubry, MD,Roy Beck, MD, PhD,Joshua Benner, PharmD, ScD,Jan E. Berger, MD, MJ,A. Mark Fendrick, MD,Felicia Forma, BSc,Dana Goldman, PhD,Anne Peters, MD,Rebecca Killion, MA,Darius Lakdawalla, PhD,Douglas K. Owens, MD,Joe Stahl, MA

February 12th 2013

Formularies of the future should use evidence-produced CER to better target, not limit, diabetes care.

Latest Updated Articles

Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
February 12th 2013
Comparative Effectiveness Research and Formulary Placement: The Case of Diabetes
July 2nd 2013
Improving Patient-Centered Care in Diabetes With Comparative Effectiveness Research
September 30th 2013

Trending on AJMC

Patient Portal Messages Outpace Office Visits

Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors

Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly

A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD

FDA Issues Complete Response Letter for Cytisinicline NDA, Citing Manufacturing Deficiencies